Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 397 entries
Sorted by: Best Match Show Resources per page
5-HT6 receptors and Alzheimer's disease.

Alzheimer's research & therapy

Ramírez MJ.
PMID: 23607787
Alzheimers Res Ther. 2013 Apr 22;5(2):15. doi: 10.1186/alzrt169. eCollection 2013.

During the past 20 years, the 5-HT6 receptor has received increasing attention and become a promising target for improving cognition. Several studies with structurally different compounds have shown that not only antagonists but also 5-HT6 receptor agonists improve learning...

Cite
Ramírez MJ. 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013;5(2):15doi: 10.1186/alzrt169.
Ramírez, M. J. (2013). 5-HT6 receptors and Alzheimer's disease. Alzheimer's research & therapy, 5(2), 15. https://doi.org/10.1186/alzrt169
Ramírez, María Javier. "5-HT6 receptors and Alzheimer's disease." Alzheimer's research & therapy vol. 5,2 (2013): 15. doi: https://doi.org/10.1186/alzrt169
Ramírez MJ. 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013 Apr 22;5(2):15. doi: 10.1186/alzrt169. eCollection 2013. PMID: 23607787; PMCID: PMC3706851.
Copy Download .nbib Format: NLM
For debate: substituting placebo controls in long-term Alzheimer's prevention trials.

Alzheimer's research & therapy

Spiegel R, Berres M, Miserez AR, Monsch AU.
PMID: 21418632
Alzheimers Res Ther. 2011 Mar 21;3(2):9. doi: 10.1186/alzrt68.

INTRODUCTION: Novel compounds with potential to attenuate or stop the progression of Alzheimer's disease (AD) from its presymptomatic stage to dementia are being tested in man. The study design commonly used is the long-term randomized, placebo-controlled trial (RPCT), meaning...

Cite
Spiegel R, Berres M, Miserez AR, et al. For debate: substituting placebo controls in long-term Alzheimer's prevention trials. Alzheimers Res Ther. 2011;3(2):9doi: 10.1186/alzrt68.
Spiegel, R., Berres, M., Miserez, A. R., Monsch, A. U. (2011). For debate: substituting placebo controls in long-term Alzheimer's prevention trials. Alzheimer's research & therapy, 3(2), 9. https://doi.org/10.1186/alzrt68
Spiegel, René, et al. "For debate: substituting placebo controls in long-term Alzheimer's prevention trials." Alzheimer's research & therapy vol. 3,2 (2011): 9. doi: https://doi.org/10.1186/alzrt68
Spiegel R, Berres M, Miserez AR, Monsch AU. For debate: substituting placebo controls in long-term Alzheimer's prevention trials. Alzheimers Res Ther. 2011 Mar 21;3(2):9. doi: 10.1186/alzrt68. PMID: 21418632; PMCID: PMC3226271.
Copy Download .nbib Format: NLM
Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease.

Alzheimer's research & therapy

Lannfelt L, Möller C, Basun H, Osswald G, Sehlin D, Satlin A, Logovinsky V, Gellerfors P.
PMID: 25031633
Alzheimers Res Ther. 2014 Mar 24;6(2):16. doi: 10.1186/alzrt246. eCollection 2014.

The symptomatic drugs currently on the market for Alzheimer's disease (AD) have no effect on disease progression, and this creates a large unmet medical need. The type of drug that has developed most rapidly in the last decade is...

Cite
Lannfelt L, Möller C, Basun H, et al. Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res Ther. 2014;6(2):16doi: 10.1186/alzrt246.
Lannfelt, L., Möller, C., Basun, H., Osswald, G., Sehlin, D., Satlin, A., Logovinsky, V., & Gellerfors, P. (2014). Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimer's research & therapy, 6(2), 16. https://doi.org/10.1186/alzrt246
Lannfelt, Lars, et al. "Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease." Alzheimer's research & therapy vol. 6,2 (2014): 16. doi: https://doi.org/10.1186/alzrt246
Lannfelt L, Möller C, Basun H, Osswald G, Sehlin D, Satlin A, Logovinsky V, Gellerfors P. Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res Ther. 2014 Mar 24;6(2):16. doi: 10.1186/alzrt246. eCollection 2014. PMID: 25031633; PMCID: PMC4054967.
Copy Download .nbib Format: NLM
Lewy body dementia: the impact on patients and caregivers.

Alzheimer's research & therapy

Zweig YR, Galvin JE.
PMID: 25031635
Alzheimers Res Ther. 2014 Apr 25;6(2):21. doi: 10.1186/alzrt251. eCollection 2014.

Lewy body dementia (LBD) is the second most common neurodegenerative dementia in older adults, yet there remains a delay in diagnosis that limits healthcare providers' ability to maximize therapeutic outcomes and enhance patient and caregiver quality of life. The...

Cite
Zweig YR, Galvin JE. Lewy body dementia: the impact on patients and caregivers. Alzheimers Res Ther. 2014;6(2):21doi: 10.1186/alzrt251.
Zweig, Y. R., & Galvin, J. E. (2014). Lewy body dementia: the impact on patients and caregivers. Alzheimer's research & therapy, 6(2), 21. https://doi.org/10.1186/alzrt251
Zweig, Yael R, and Galvin, James E. "Lewy body dementia: the impact on patients and caregivers." Alzheimer's research & therapy vol. 6,2 (2014): 21. doi: https://doi.org/10.1186/alzrt251
Zweig YR, Galvin JE. Lewy body dementia: the impact on patients and caregivers. Alzheimers Res Ther. 2014 Apr 25;6(2):21. doi: 10.1186/alzrt251. eCollection 2014. PMID: 25031635; PMCID: PMC4054937.
Copy Download .nbib Format: NLM
Truncated and modified amyloid-beta species.

Alzheimer's research & therapy

Kummer MP, Heneka MT.
PMID: 25031638
Alzheimers Res Ther. 2014 May 26;6(3):28. doi: 10.1186/alzrt258. eCollection 2014.

Alzheimer's disease pathology is closely connected to the processing of the amyloid precursor protein (APP) resulting in the formation of a variety of amyloid-beta (Aβ) peptides. They are found as insoluble aggregates in senile plaques, the histopathological hallmark of...

Cite
Kummer MP, Heneka MT. Truncated and modified amyloid-beta species. Alzheimers Res Ther. 2014;6(3):28doi: 10.1186/alzrt258.
Kummer, M. P., & Heneka, M. T. (2014). Truncated and modified amyloid-beta species. Alzheimer's research & therapy, 6(3), 28. https://doi.org/10.1186/alzrt258
Kummer, Markus P, and Heneka, Michael T. "Truncated and modified amyloid-beta species." Alzheimer's research & therapy vol. 6,3 (2014): 28. doi: https://doi.org/10.1186/alzrt258
Kummer MP, Heneka MT. Truncated and modified amyloid-beta species. Alzheimers Res Ther. 2014 May 26;6(3):28. doi: 10.1186/alzrt258. eCollection 2014. PMID: 25031638; PMCID: PMC4055046.
Copy Download .nbib Format: NLM
Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography.

Alzheimer's research & therapy

Sha SJ, Ghosh PM, Lee SE, Corbetta-Rastelli C, Jagust WJ, Kornak J, Rankin KP, Grinberg LT, Vinters HV, Mendez MF, Dickson DW, Seeley WW, Gorno-Tempini M, Kramer J, Miller BL, Boxer AL, Rabinovici GD.
PMID: 25733984
Alzheimers Res Ther. 2015 Mar 02;7(1):8. doi: 10.1186/s13195-014-0093-y. eCollection 2015.

INTRODUCTION: Group comparisons demonstrate greater visuospatial and memory deficits and temporoparietal-predominant degeneration on neuroimaging in patients with corticobasal syndrome (CBS) found to have Alzheimer's disease (AD) pathology versus those with underlying frontotemporal lobar degeneration (FTLD). The value of these...

Cite
Sha SJ, Ghosh PM, Lee SE, et al. Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimers Res Ther. 2015;7(1):8doi: 10.1186/s13195-014-0093-y.
Sha, S. J., Ghosh, P. M., Lee, S. E., Corbetta-Rastelli, C., Jagust, W. J., Kornak, J., Rankin, K. P., Grinberg, L. T., Vinters, H. V., Mendez, M. F., Dickson, D. W., Seeley, W. W., Gorno-Tempini, M., Kramer, J., Miller, B. L., Boxer, A. L., & Rabinovici, G. D. (2015). Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimer's research & therapy, 7(1), 8. https://doi.org/10.1186/s13195-014-0093-y
Sha, Sharon J, et al. "Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography." Alzheimer's research & therapy vol. 7,1 (2015): 8. doi: https://doi.org/10.1186/s13195-014-0093-y
Sha SJ, Ghosh PM, Lee SE, Corbetta-Rastelli C, Jagust WJ, Kornak J, Rankin KP, Grinberg LT, Vinters HV, Mendez MF, Dickson DW, Seeley WW, Gorno-Tempini M, Kramer J, Miller BL, Boxer AL, Rabinovici GD. Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimers Res Ther. 2015 Mar 02;7(1):8. doi: 10.1186/s13195-014-0093-y. eCollection 2015. PMID: 25733984; PMCID: PMC4346122.
Copy Download .nbib Format: NLM
Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research.

Alzheimer's research & therapy

Ritchie CW, Terrera GM, Quinn TJ.
PMID: 25788988
Alzheimers Res Ther. 2015 Mar 18;7(1):31. doi: 10.1186/s13195-015-0113-6. eCollection 2015.

Dementia is a substantial and increasing public health concern. Despite decades of research, a cure or effective preventative treatment for dementia remains elusive. We offer critical review of contemporary dementia research and discuss potential reasons why progress in the...

Cite
Ritchie CW, Terrera GM, Quinn TJ. Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research. Alzheimers Res Ther. 2015;7(1):31doi: 10.1186/s13195-015-0113-6.
Ritchie, C. W., Terrera, G. M., & Quinn, T. J. (2015). Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research. Alzheimer's research & therapy, 7(1), 31. https://doi.org/10.1186/s13195-015-0113-6
Ritchie, Craig W, et al. "Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research." Alzheimer's research & therapy vol. 7,1 (2015): 31. doi: https://doi.org/10.1186/s13195-015-0113-6
Ritchie CW, Terrera GM, Quinn TJ. Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research. Alzheimers Res Ther. 2015 Mar 18;7(1):31. doi: 10.1186/s13195-015-0113-6. eCollection 2015. PMID: 25788988; PMCID: PMC4364079.
Copy Download .nbib Format: NLM
Imaging endpoints for clinical trials in Alzheimer's disease.

Alzheimer's research & therapy

Cash DM, Rohrer JD, Ryan NS, Ourselin S, Fox NC.
PMID: 25621018
Alzheimers Res Ther. 2014 Dec 20;6(9):87. doi: 10.1186/s13195-014-0087-9. eCollection 2014.

As the need to develop a successful disease-modifying treatment for Alzheimer's disease (AD) becomes more urgent, imaging is increasingly used in therapeutic trials. We provide an overview of how the different imaging modalities are used in AD studies and...

Cite
Cash DM, Rohrer JD, Ryan NS, et al. Imaging endpoints for clinical trials in Alzheimer's disease. Alzheimers Res Ther. 2014;6(9):87doi: 10.1186/s13195-014-0087-9.
Cash, D. M., Rohrer, J. D., Ryan, N. S., Ourselin, S., & Fox, N. C. (2014). Imaging endpoints for clinical trials in Alzheimer's disease. Alzheimer's research & therapy, 6(9), 87. https://doi.org/10.1186/s13195-014-0087-9
Cash, David M, et al. "Imaging endpoints for clinical trials in Alzheimer's disease." Alzheimer's research & therapy vol. 6,9 (2014): 87. doi: https://doi.org/10.1186/s13195-014-0087-9
Cash DM, Rohrer JD, Ryan NS, Ourselin S, Fox NC. Imaging endpoints for clinical trials in Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 20;6(9):87. doi: 10.1186/s13195-014-0087-9. eCollection 2014. PMID: 25621018; PMCID: PMC4304258.
Copy Download .nbib Format: NLM
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease.

Alzheimer's research & therapy

Vassar R.
PMID: 25621019
Alzheimers Res Ther. 2014 Dec 24;6(9):89. doi: 10.1186/s13195-014-0089-7. eCollection 2014.

β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the β-secretase enzyme required for the production of the neurotoxic β-amyloid (Aβ) peptide that is widely considered to have a crucial early role in the etiology of Alzheimer's disease (AD)....

Cite
Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014;6(9):89doi: 10.1186/s13195-014-0089-7.
Vassar, R. (2014). BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimer's research & therapy, 6(9), 89. https://doi.org/10.1186/s13195-014-0089-7
Vassar, Robert. "BACE1 inhibitor drugs in clinical trials for Alzheimer's disease." Alzheimer's research & therapy vol. 6,9 (2014): 89. doi: https://doi.org/10.1186/s13195-014-0089-7
Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89. doi: 10.1186/s13195-014-0089-7. eCollection 2014. PMID: 25621019; PMCID: PMC4304279.
Copy Download .nbib Format: NLM
A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid.

Alzheimer's research & therapy

Yang T, O'Malley TT, Kanmert D, Jerecic J, Zieske LR, Zetterberg H, Hyman BT, Walsh DM, Selkoe DJ.
PMID: 25802556
Alzheimers Res Ther. 2015 Mar 22;7(1):14. doi: 10.1186/s13195-015-0100-y. eCollection 2015.

INTRODUCTION: Amyloid β-protein oligomers play a key role in Alzheimer's disease (AD), but well-validated assays that routinely detect them in cerebrospinal fluid (CSF) are just emerging. We sought to confirm and extend a recent study using the Singulex Erenna...

Cite
Yang T, O'Malley TT, Kanmert D, et al. A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid. Alzheimers Res Ther. 2015;7(1):14doi: 10.1186/s13195-015-0100-y.
Yang, T., O'Malley, T. T., Kanmert, D., Jerecic, J., Zieske, L. R., Zetterberg, H., Hyman, B. T., Walsh, D. M., & Selkoe, D. J. (2015). A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid. Alzheimer's research & therapy, 7(1), 14. https://doi.org/10.1186/s13195-015-0100-y
Yang, Ting, et al. "A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid." Alzheimer's research & therapy vol. 7,1 (2015): 14. doi: https://doi.org/10.1186/s13195-015-0100-y
Yang T, O'Malley TT, Kanmert D, Jerecic J, Zieske LR, Zetterberg H, Hyman BT, Walsh DM, Selkoe DJ. A highly sensitive novel immunoassay specifically detects low levels of soluble Aβ oligomers in human cerebrospinal fluid. Alzheimers Res Ther. 2015 Mar 22;7(1):14. doi: 10.1186/s13195-015-0100-y. eCollection 2015. PMID: 25802556; PMCID: PMC4369838.
Copy Download .nbib Format: NLM
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer's disease: an emerging method based upon brain dynamics.

Alzheimer's research & therapy

van Straaten EC, Scheltens P, Gouw AA, Stam CJ.
PMID: 25621017
Alzheimers Res Ther. 2014 Dec 19;6(9):86. doi: 10.1186/s13195-014-0086-x. eCollection 2014.

Electroencephalography (EEG) is a longstanding technique to measure electrical brain activity and thereby an indirect measure of synaptic activity. Synaptic dysfunction accompanies Alzheimer's disease (AD) and EEG can be regarded as a potentially useful biomarker in this disease. Lately,...

Cite
van Straaten EC, Scheltens P, Gouw AA, et al. Eyes-closed task-free electroencephalography in clinical trials for Alzheimer's disease: an emerging method based upon brain dynamics. Alzheimers Res Ther. 2014;6(9):86doi: 10.1186/s13195-014-0086-x.
van Straaten, E. C., Scheltens, P., Gouw, A. A., & Stam, C. J. (2014). Eyes-closed task-free electroencephalography in clinical trials for Alzheimer's disease: an emerging method based upon brain dynamics. Alzheimer's research & therapy, 6(9), 86. https://doi.org/10.1186/s13195-014-0086-x
van Straaten, Elisabeth Cw, et al. "Eyes-closed task-free electroencephalography in clinical trials for Alzheimer's disease: an emerging method based upon brain dynamics." Alzheimer's research & therapy vol. 6,9 (2014): 86. doi: https://doi.org/10.1186/s13195-014-0086-x
van Straaten EC, Scheltens P, Gouw AA, Stam CJ. Eyes-closed task-free electroencephalography in clinical trials for Alzheimer's disease: an emerging method based upon brain dynamics. Alzheimers Res Ther. 2014 Dec 19;6(9):86. doi: 10.1186/s13195-014-0086-x. eCollection 2014. PMID: 25621017; PMCID: PMC4304266.
Copy Download .nbib Format: NLM
The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer's disease: results from a cohort study.

Alzheimer's research & therapy

Droogsma E, van Asselt D, Bieze H, Veeger N, De Deyn PP.
PMID: 25848400
Alzheimers Res Ther. 2015 Apr 06;7(1):18. doi: 10.1186/s13195-015-0098-1. eCollection 2015.

INTRODUCTION: Weight loss has been described in 20% to 45% of patients with Alzheimer's disease (AD) and has been associated with adverse outcomes. Various mechanisms for weight loss in AD patients have been proposed, though none has been proven....

Cite
Droogsma E, van Asselt D, Bieze H, et al. The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer's disease: results from a cohort study. Alzheimers Res Ther. 2015;7(1):18doi: 10.1186/s13195-015-0098-1.
Droogsma, E., van Asselt, D., Bieze, H., Veeger, N., & De Deyn, P. P. (2015). The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer's disease: results from a cohort study. Alzheimer's research & therapy, 7(1), 18. https://doi.org/10.1186/s13195-015-0098-1
Droogsma, Erika, et al. "The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer's disease: results from a cohort study." Alzheimer's research & therapy vol. 7,1 (2015): 18. doi: https://doi.org/10.1186/s13195-015-0098-1
Droogsma E, van Asselt D, Bieze H, Veeger N, De Deyn PP. The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer's disease: results from a cohort study. Alzheimers Res Ther. 2015 Apr 06;7(1):18. doi: 10.1186/s13195-015-0098-1. eCollection 2015. PMID: 25848400; PMCID: PMC4386098.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 397 entries